We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MIP Technologies and Supelco Launch Selective SPE Product for Extraction of Amphetamine and Related Drugs
Product News

MIP Technologies and Supelco Launch Selective SPE Product for Extraction of Amphetamine and Related Drugs

MIP Technologies and Supelco Launch Selective SPE Product for Extraction of Amphetamine and Related Drugs
Product News

MIP Technologies and Supelco Launch Selective SPE Product for Extraction of Amphetamine and Related Drugs


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "MIP Technologies and Supelco Launch Selective SPE Product for Extraction of Amphetamine and Related Drugs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MIP Technologies AB and Supelco, a division of Sigma-Aldrich Corporation has announced the launch of a new SupelMIP™ product for the selective extraction of amphetamine and related drugs.

A SPE product has been developed for trace level determinations in forensic, toxicological and pharmaceutical testing. The SPE phase has been evaluated for amphetamine, methamphetamine, phentermine, MDA, MDMA and MDEA. Recoveries are high and the extracts show minimized ion suppression in urine and oral fluids.

The product is currently being tested at the hospital laboratory in Ängelholm, Sweden. This laboratory is accredited for drug screening in workplaces and schools as well as being a confirmative testing reference site for the southern part of Sweden.

"We are very excited to test this new class-selective SPE phase," said Carl Magnusson, Head of the department of Clinical Chemistry, Ängelholm Hospital.

"This new SPE phase provides added value to the customers by being efficiently class selective and allowing for lower limits of quantitation for the confirmation of this common drug of abuse," said An Trinh, Product Manager, Supelco.

Advertisement